In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.
RWJ-416457, an investigational pyrrolopyrazolyl-substituted oxazolidinone, inhibited the growth of linezolid-susceptible staphylococci, enterococci, and streptococci at concentrations of < or =4 microg/ml, generally exhibiting two- to fourfold-greater potency than that of linezolid. Time-kill studies demonstrated bacteriostatic effects for both RWJ-416457 and linezolid.
Foleno
Barbara D
BD
Johnson and Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ 08869, USA. bfoleno@prdus.jnj.com
Abbanat
Darren
D
Goldschmidt
Raul M
RM
Flamm
Robert K
RK
Paget
Steve D
SD
Webb
Glenda C
GC
Wira
Ellyn
E
Macielag
Mark J
MJ
Bush
Karen
K
D000081:Acetamides / Q000737:chemistry; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D016983:Enterococcus / Q000187:drug effects; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D023303:Oxazolidinones / Q000737:chemistry / Q000494:pharmacology*; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; C518323:RWJ-416457; D000069349:Linezolid